LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that ...

Farid Adrienne, the Chief Operations Officer of Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold shares of the ...

PHILADELPHIA—Carr Douglas, Senior Vice President of Finance & Operations at Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 351 shares of the company's common stock. The shares were sold at a ...

LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same period last year, the firm posted ($0.55) EPS.

This page features the latest news about the Century Therapeutics share. Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell ...

4 analysts have shared their evaluations of Century Therapeutics (NASDAQ:IPSC) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find ...

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million focused on developing cell therapies for cancer and autoimmune diseases, ...